However, in agreement with the emerging concept of personalized cancer therapy, general conclusions should be avoided, and more tumor-specific biomarkers should be sought.
Place in therapy and conclusion: Evidence currently available indicates that palonosetron significantly adds to the clinician's ability to effectively control CINV in patients undergoing HEC or MEC.
If found to be at an increased risk of breast cancer progression, women who have had a previous hysterectomy may benefit from more rigorous surveillance or targeted therapy In conclusion, serum VEGF appears to be influenced by the presence of a postmenopausal uterus.
However, the lack of a control group, selection bias and the use of adjuvant androgen deprivation therapy prevent strong conclusions from published studies.
Our study was not designed to compare plasma PCR vs pp65 Ag as the best parameter for starting pre-emptive therapy; therefore, no conclusions can be made on the clinical sensitivity of PCR assay, since pre-emptive therapy was based on pp65Ag assay.
Our study is more in accordance and relevant to current practices in the U.S. (i.e., standard of care therapy); hence our conclusions are directly applicable to the majority of patients who seek medical attention after a resection of a PDA.
Van As et al. performed the first systematic review evaluating all medical interventions to assess the efficacy of different otoprotective medical interventions for preventing hearing loss in children with cancer treated with platinum-based therapy, but no conclusions were made by the author about their efficacy.
Subsequent studies have reported a potential for life-threatening or fatal adverse events with the use of long-acting beta agonist (LABA) therapy, but this conclusion must be tempered by the suboptimal design of the studies which form the foundation for these conclusions.
Conclusion: Therapy with a 4-week course of large-particle nebulized aerosol therapy improves symptomatology and objective parameters of rhinosinusitis in patients refractory to surgical and medical therapies.
In conclusion, therapy with HU cytostatic drugs and ANA can reduce PLT count in ET, and also affect endothelial modulatory agents, with HU sustaining vasodilation and prothrombotic MP concentration, whereas ANA decreases vasoconstriction.
